James Klemis, MD
Interventional Cardiology · Germantown, TNNPI 1447269659
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Shockwave Medical, Inc at 39.2% of the total. Reporting peaked in 2024 at $11,327 and has fallen 72.8% since, to $3,086 in 2025.
Across 570 payments — averaging $42.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$9K
- Medtronic$4K
- Abbott$3K
- Novartis$947
- Angiodynamics, Inc.$928
- AstraZeneca$632
- plus $6K from 43 others
Across 3 payments — averaging $2333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Contego Medical, Inc$7K
What the payments were for
- Consulting fees$3501%
- Speaking & faculty fees$6,60028%
- Travel & lodging$3,97317%
- Food & beverage$13,03554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,918
- AlphaVac$869
- ENROUTE Transcarotid Neuroprotection System$700
- MitraClip$352
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$350
- ENROUTE Transcarotid Stent$350
- Perclose ProGlide suture mediated closure system$261
- XACT$252
- FFRct$245
- Impella$230
- GORE VIABAHN VBX Balloon Expandable Endo$177
- Micra$174
- ESPRIT$171
- Repatha$142
- EPI-EASE EPICARDIAL ACCESS SYSTEM$135
- Supera peripheral stent system$135
- Indigo System$126
- TherOx DS2 Console$120
- Catheter$120
- Downstream Cartridge$120
How this compares
$23,958 in reported general payments places this provider in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 535 | $452,984 |
| EntrestoSacubitril/Valsartan | 241 | $214,455 |
| Repatha SureclickEvolocumab | 88 | $56,308 |
| JardianceEmpagliflozin | 65 | $51,039 |
| XareltoRivaroxaban | 64 | $41,496 |
| BrilintaTicagrelor | 58 | $34,041 |
| FarxigaDapagliflozin Propanediol | 21 | $13,753 |
| Ranolazine ErRanolazine | 138 | $13,133 |
| ClopidogrelClopidogrel Bisulfate | 767 | $6,074 |
| Metoprolol Succinate | 405 | $4,250 |
| Atorvastatin Calcium | 423 | $4,011 |
| Rosuvastatin Calcium | 224 | $2,229 |
| Losartan Potassium | 238 | $2,109 |
| Cilostazol | 103 | $1,861 |
| Prasugrel Hcl | 25 | $1,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $172 | $452,984535 claims |
| NovartisEntresto | $947 | $214,455241 claims |
| Boehringer IngelheimJardiance | $250 | $51,03965 claims |
| AstraZenecaBrilinta, Farxiga | $632 | $47,79479 claims |
| Johnson & JohnsonXarelto | $148 | $41,49664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Germantown
- Mehul PatelGermantown$382K
- David KrausGermantown$87K
- Basil PaulusGermantown$67K
- Justin MayGermantown$23K
- Tamunoinemi Bob-ManuelGermantown$22K
- Milton AddingtonGermantown$15K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.